Oncotargets and Therapy Dovepress Current Classification, Treatment Options, and New Perspectives in the Management of Adipocytic Sarcomas
暂无分享,去创建一个
D. Amadori | A. De Vita | F. Recine | T. Ibrahim | L. Mercatali | N. Riva | C. Liverani | Alberto Bongiovanni | F. Pieri | C. Spadazzi | G. Miserocchi
[1] Robin L. Jones,et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Blay,et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial , 2016, The Lancet.
[3] Dafydd G. Thomas,et al. SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma , 2016, Cancer.
[4] A. Banerjee,et al. Impact of chemotherapy on survival in surgically resected retroperitoneal sarcoma. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[5] B. Chetaille,et al. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas , 2015, Modern Pathology.
[6] R. Abrams,et al. Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel. , 2015, International journal of radiation oncology, biology, physics.
[7] J. Blay,et al. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] L. Qin,et al. Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma , 2015, Sarcoma.
[9] Lon Smith,et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.
[10] A. Crago,et al. Extended Surgical Resection and Histology in Retroperitoneal Sarcoma , 2015, Annals of Surgical Oncology.
[11] A. L. Risinger,et al. Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent , 2015, Clinical Cancer Research.
[12] N. Araki,et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. , 2015, The Lancet. Oncology.
[13] W. Ceelen,et al. Retroperitoneal Liposarcoma: Current Insights in Diagnosis and Treatment , 2015, Front. Surg..
[14] Robin L. Jones,et al. Trabectedin in Soft Tissue Sarcomas , 2015, Marine drugs.
[15] Haiyong Wang,et al. Advances in the targeted therapy of liposarcoma , 2015, OncoTargets and therapy.
[16] C M Galmarini,et al. Mode of action of trabectedin in myxoid liposarcomas , 2014, Oncogene.
[17] Y. Oda,et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models , 2014, Cancer science.
[18] C. Antonescu,et al. Lessons Learned From the Study of 10,000 Patients With Soft Tissue Sarcoma , 2014, Annals of surgery.
[19] J. Park,et al. Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma , 2014, Oncotarget.
[20] Yoon-La Choi,et al. CDK4 Amplification Predicts Recurrence of Well-Differentiated Liposarcoma of the Abdomen , 2014, PloS one.
[21] S. Pilotti,et al. Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP‐1 and TIMP‐2 and tumor thrombospondin‐1 , 2014, International journal of cancer.
[22] P. Allavena,et al. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment , 2014, British Journal of Cancer.
[23] J. Blay,et al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. , 2014, European journal of cancer.
[24] Khin Thway,et al. Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies , 2014, Nature Reviews Clinical Oncology.
[25] J. Blay,et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. , 2014, The Lancet. Oncology.
[26] T. Yoshida,et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states , 2014, British Journal of Cancer.
[27] C. Fletcher. The evolving classification of soft tissue tumours – an update based on the new 2013 WHO classification , 2014, Histopathology.
[28] Robin L. Jones,et al. Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma , 2013, Sarcoma.
[29] G. Shapiro,et al. Abstract A276: Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas. , 2013 .
[30] M. Stanojevic,et al. p14ARF methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma , 2013, Medical Oncology.
[31] L. Qin,et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] G. Demetri,et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] A. Lazar,et al. Novel Systemic Therapies in Advanced Liposarcoma: A Review of Recent Clinical Trial Results , 2013, Cancers.
[34] P. Allavena,et al. New activities for the anti-tumor agent trabectedin: taking two birds with one stone , 2013, Oncotarget.
[35] M. Zucchetti,et al. Role of macrophage targeting in the antitumor activity of trabectedin. , 2013, Cancer cell.
[36] K. Griffith,et al. Phase II Trial of Cetuximab in Patients With Metastatic or Locally Advanced Soft Tissue or Bone Sarcoma , 2013, American journal of clinical oncology.
[37] P. D. Dal Cin,et al. Well‐differentiated and dedifferentiated liposarcomas with prominent myxoid stroma: analysis of 56 cases , 2013, Histopathology.
[38] L. Dodd. Update on Liposarcoma: A review for cytopathologists , 2012, Diagnostic cytopathology.
[39] G. Demetri,et al. A phase 1 study of efatutazone, an oral peroxisome proliferator‐activated receptor gamma agonist, administered to patients with advanced malignancies , 2012, Cancer.
[40] Jean-Yves Blay,et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. , 2012, The Lancet. Oncology.
[41] P. Frankel,et al. Phase I study of nelfinavir in liposarcoma , 2012, Cancer Chemotherapy and Pharmacology.
[42] B. Bui,et al. Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] Dafydd G. Thomas,et al. Cutaneous and Subcutaneous Pleomorphic Liposarcoma: A Clinicopathologic Study of 29 Cases With Evaluation of MDM2 Gene Amplification in 26 , 2012, The American journal of surgical pathology.
[44] C. Antonescu,et al. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] D. Cavalieri,et al. A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma , 2012, PloS one.
[46] K. Horiuchi,et al. Metastatic Patterns of Myxoid/Round Cell Liposarcoma: A Review of a 25-Year Experience , 2012, Sarcoma.
[47] L. Mariani,et al. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] J. Blay,et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] S. Singer,et al. The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial , 2012, Clinical Cancer Research.
[50] J. Goldblum,et al. Phase 2 Southwest Oncology Group‐directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas , 2012, Cancer.
[51] Wei-Lien Wang,et al. Liposarcoma in children and young adults: A multi‐institutional experience , 2011, Pediatric blood & cancer.
[52] Shengle Zhang,et al. DDIT3 Gene Break-apart as a Molecular Marker for Diagnosis of Myxoid Liposarcoma—Assay Validation and Clinical Experience , 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[53] Gang Han,et al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma , 2011, International journal of cancer.
[54] J. Blay,et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. , 2011, The Lancet. Oncology.
[55] J. Blay,et al. Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing , 2011, PloS one.
[56] H. Iwasaki,et al. Cytogenetics and Molecular Genetics of Myxoid Soft-Tissue Sarcomas , 2011, Genetics research international.
[57] S. Singer,et al. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma , 2011, Current opinion in oncology.
[58] J. Blay,et al. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[59] C. Creighton,et al. Diagnosis, Management, and Outcome of Patients with Dedifferentiated Liposarcoma Systemic Metastasis , 2011, Annals of Surgical Oncology.
[60] Chris Twelves,et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011, The Lancet.
[61] David M. Thomas,et al. Liposarcoma: Molecular Genetics and Therapeutics , 2010, Sarcoma.
[62] T. Hasegawa,et al. Myxoid liposarcoma with EWS-CHOP type 1 fusion gene. , 2010, Anticancer research.
[63] C. Galmarini,et al. A Review of Trabectedin (ET-743): A Unique Mechanism of Action , 2010, Molecular Cancer Therapeutics.
[64] Derek Y. Chiang,et al. Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy , 2010, Nature Genetics.
[65] S. Sleijfer,et al. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. , 2010, The oncologist.
[66] T. Schultheiss,et al. Radiotherapy and extent of surgical resection in retroperitoneal soft‐tissue sarcoma: Multi‐institutional analysis of 261 patients , 2010, Journal of surgical oncology.
[67] P. Schirmacher,et al. Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathways , 2010, Virchows Archiv.
[68] J. Blay,et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] F. Grosso,et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[70] L. White,et al. Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma , 2009, Cancer.
[71] L. Qin,et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] Patrick Schöffski,et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] F. Grosso,et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors , 2009, Molecular Cancer Therapeutics.
[74] D. Jong,et al. Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis , 2009, Modern Pathology.
[75] F. Abdul-Karim,et al. Radiation Therapy in Addition to Gross Total Resection of Retroperitoneal Sarcoma Results in Prolonged Survival: Results from a Single Institutional Study , 2009, Journal of oncology.
[76] F. Farrokhyar,et al. A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma , 2008, Cancer.
[77] F. Chibon,et al. Clinical and Biological Significance of CDK4 Amplification in Well-Differentiated and Dedifferentiated Liposarcomas , 2008, Clinical Cancer Research.
[78] C. Antonescu,et al. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging , 2007, Cancer.
[79] C. Sander,et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. , 2007, Cancer research.
[80] O. Myklebost,et al. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin‐3A , 2007, International journal of cancer.
[81] L. Mariani,et al. Myxoid/round cell and pleomorphic liposarcomas , 2007, Cancer.
[82] P. Workman,et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days , 2006, British Journal of Cancer.
[83] J. Desai,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[84] H. Yoshikawa,et al. A novel type of EWS-CHOP fusion gene in myxoid liposarcoma. , 2006, Biochemical and biophysical research communications.
[85] W. Chow,et al. Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1 , 2006, Anti-cancer drugs.
[86] M. Kattan,et al. Subtype Specific Prognostic Nomogram for Patients With Primary Liposarcoma of the Retroperitoneum, Extremity, or Trunk , 2006, Annals of surgery.
[87] Robin L. Jones,et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. , 2005, European journal of cancer.
[88] Y. Iwamoto,et al. Frequent alteration of p16INK4a/p14ARF and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14ARF expression both correlate with poor prognosis , 2005, The Journal of pathology.
[89] P. A. Pérez-Mancera,et al. Understanding mesenchymal cancer: the liposarcoma-associated FUS-DDIT3 fusion gene as a model. , 2005, Seminars in cancer biology.
[90] H. Taubert,et al. Gains of 13q are correlated with a poor prognosis in liposarcoma , 2005, Modern Pathology.
[91] M. Gariboldi,et al. Gene expression profile identifies a rare epithelioid variant case of pleomorphic liposarcoma carrying FUS‐CHOP transcript , 2005, Histopathology.
[92] O. Mariani,et al. Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances , 2005, Laboratory Investigation.
[93] C. Fletcher,et al. Pleomorphic Liposarcoma: Clinicopathologic Analysis of 57 Cases , 2004, The American journal of surgical pathology.
[94] Tim Eisen,et al. Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma , 2004, Clinical Cancer Research.
[95] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[96] J. Coindre,et al. Evaluation of MDM2 and CDK4 amplification by real‐time PCR on paraffin wax‐embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well‐differentiated liposarcomas , 2004, The Journal of pathology.
[97] R. Sciot,et al. A phase II trial with rosiglitazone in liposarcoma patients , 2003, British Journal of Cancer.
[98] B. Morrison. Soft Tissue Sarcomas of the Extremities , 2003, Proceedings.
[99] J. Thomas,et al. Amputation for soft-tissue sarcoma. , 2003, The Lancet. Oncology.
[100] Samuel Singer,et al. Histologic Subtype and Margin of Resection Predict Pattern of Recurrence and Survival for Retroperitoneal Liposarcoma , 2003, Annals of surgery.
[101] B. Feig,et al. Surgical management of soft tissue sarcomas of the hand and foot , 2002, Cancer.
[102] A. Davis,et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial , 2002, The Lancet.
[103] D. Sargent,et al. Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. , 2002, International journal of radiation oncology, biology, physics.
[104] M. Ladanyi,et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[105] M Bonetti,et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[106] E. Montgomery,et al. Pleomorphic Liposarcoma: A Clinicopathologic Analysis Of 19 Cases , 2001, Modern Pathology.
[107] A. D. Tos. Liposarcoma: new entities and evolving concepts. , 2000, Annals of diagnostic pathology.
[108] J. Manola,et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[109] B. Spiegelman,et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[110] J M Woodruff,et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. , 1998, Annals of surgery.
[111] A. D. Dei Tos,et al. Primary liposarcoma of the skin: a rare neoplasm with unusual high grade features. , 1998, The American Journal of dermatopathology.
[112] T. Ishida,et al. Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. , 1997, The American journal of pathology.
[113] M. Heslin,et al. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[114] B. Spiegelman,et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[115] E. Casper,et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] A. Santoro,et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] A. Hart,et al. Resectable retroperitoneal soft tissue sarcomas. The effect of extent of resection and postoperative radiation therapy on local tumor control , 1994, Cancer.
[118] T. Eberlein,et al. Prognostic Factors Predictive of Survival and Local Recurrence for Extremity Soft Tissue Sarcoma , 1994, Annals of surgery.
[119] A. Rydholm,et al. Limb-sparing surgery without radiotherapy based on anatomic location of soft tissue sarcoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[120] D. Rosenthal,et al. Treatment of the patient with stage M0 soft tissue sarcoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] C. Karakousis,et al. Feasibility of limb salvage and survival in soft tissue sarcomas , 1986, Cancer.
[122] J. Tepper,et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. , 1982, Annals of surgery.
[123] E. Ewing. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[124] C. Mussi,et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[125] V. Sondak,et al. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. , 2008, Cancer control : journal of the Moffitt Cancer Center.
[126] P. Thall,et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] L. Mariani,et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[128] Y. Nakamura,et al. Soft-Tissue Sarcomas , 2003 .
[129] S. Steinberg,et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[130] C. Catton,et al. Outcome and prognosis in retroperitoneal soft tissue sarcoma. , 1994, International journal of radiation oncology, biology, physics.
[131] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[132] E. Grande,et al. Oncotargets and Therapy , 2022 .
[133] Theodore Leng,et al. submit your manuscript | www.dovepress.com , 2022 .